Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus
Before their memory is affected, many individuals with Alzheimer’s disease (AD) may experience trouble sleeping, lose their daily rhythms, and show changes in metabolism and stress hormones. These functions are regulated by the hypothalamus, a structure at the base of the brain. A study headed by researchers at the Buck Institute for Research on Aging has now found that the hypothalamus is not a bystander in Alzheimer’s disease, and its circadian and metabolic control centers show specific age-related changes in volume and gene activity early in the disease.
For their study, the team combined measurements from brain images and single-nucleus RNA sequencing maps to build a resource, HypoAD, as an atlas of the human hypothalamus in aging and AD, which they have made available to the research community.
Ashley Webb, PhD, associate professor at the Buck Institute for Research on Aging, is senior and co-corresponding author of the team’s published report in Nature, titled “Hypothalamic volume and cell-type changes in aging and Alzheimer’s disease,” in which they concluded, “Our findings provide a multimodal view of how the hypothalamus is altered in aging and early AD, illustrating region-specific and cell-type-specific changes that have not been observed previously.”
AD is an age-associated neurodegenerative disorder with a prevalence of roughly 10–30% among individuals older than 65 years, the authors wrote. And while the main feature is cognitive decline, they stated, “… AD manifests as a systemic condition involving profound disruptions in sleep, circadian rhythms, metabolic homeostasis, stress responses, and neuroendocrine functions.” These key processes are regulated by the hypothalamus, a small, complex part of the brain that orchestrates a wide range of physiological and neuroendocrine processes that are commonly dysregulated in aging and AD.
“Emerging evidence suggests that hypothalamic dysfunction not only correlates with but also actively exacerbates AD pathology and cognitive decline,” the team noted. However, they pointed out, “Despite its central role in homeostasis and brain aging, the hypothalamus remains an understudied region in the context of human aging and AD.”
Webb noted, “Most of what we know about Alzheimer’s comes from the hippocampus and cortex, because that’s where memory is organized and lives. But patients and families often report disrupted sleep, a change in appetite, or different responses to stress alongside memory changes.”
The hypothalamus is made up of many specialized sub-areas called nuclei. Each nucleus runs a different job. The suprachiasmatic nucleus (SCN) is the body’s master clock, while the arcuate nucleus (ARC) handles appetite and energy balance. Very little is known about how the individual nuclei and their cell types change in human aging and Alzheimer’s.
“No single method can answer this question,” said co-senior author Manu Goyal, MD, director of neuroimaging labs at Washington University School of Medicine in St. Louis. “MRI can tell you what’s happening in living people but is limited in its resolution. Single-cell sequencing tells you what’s happening inside each cell type but requires actual tissue. The goal here was to put them side by side to let us see things that neither could show alone.”
Noting that recent studies even suggest that changes such as circadian disruptions may precede the development of other common clinical symptoms, Webb added, “We wanted to look directly at the part of the brain that controls those functions, and to do it with enough resolution to see which cells are changing with age and in the disease.”
To better enable this insight, the team created HypoAD as an atlas of the human hypothalamus in aging and AD, by combining high-resolution magnetic resonance imaging from hundreds of individuals and single-nucleus RNA sequencing of more than 600,000 nuclei from young participants, patients with AD, and age-matched non-dementia control participants.
![Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s Disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann]](https://www.genengnews.com/wp-content/uploads/2026/11/Low-Res_Volumes-300x160.jpg)
Three-dimensional reconstructions of hypothalamic subregions from MRI scans of two female individuals at 72 years of age, one healthy (left) and one with Alzheimer’s disease (right). Differences in volume can be observed in regions involved in regions labeled SCN, AN, and Pe, which are important for sleep, circadian rhythms, and metabolic regulation. [Jürgen Germann]
Using MRI scans from 458 living adults and a high-resolution atlas, the researchers measured the volume of 13 separate hypothalamic sub-regions. Participants were grouped by cognitive status and by levels of amyloid-β, the protein that forms plaques in Alzheimer’s disease. The team then sequenced about 614,000 individual cells from post-mortem hypothalamic tissue. This method shows which genes are switched on in each cell, so changes can be traced to specific cell types and cellular functions. Donors included seven people with mostly early-stage Alzheimer’s disease, seven age-matched healthy controls, and three younger people from published data.
The researchers validated their findings against spinal fluid protein measurements, a prefrontal cortex dataset from about 800 donors, spatial gene-expression maps, and a mouse model of Alzheimer’s.
The scientists found that though overall hypothalamic volume barely changed with age, different areas of the hypothalamus did either change or increase in volume. The lateral hypothalamus shrank with age, while the SCN, arcuate, paraventricular, periventricular, and dorsomedial hypothalamic nuclei (DMH) grew. Webb said this phenomenon held after accounting for Alzheimer’s disease status, suggesting it is a feature of typical aging. “Together, these findings suggest that hypothalamic nuclei undergo differential volumetric changes with aging, even in the absence of AD,” the investigators noted.
Volume differences tied specifically to AD also occurred but weren’t statistically significant, suggesting that a more sensitive method might be needed to determine what happens with the Alzheimer’s hypothalamus. “… in comparison to aging and sex, differences in the volumes of hypothalamic nuclei in the context of amyloid-β deposition and cognitive impairment were more modest or absent,” they noted.
“If you only measure the hypothalamus as a whole, it looks like nothing is happening,” Webb said. “When you zoom in, you see some regions shrinking and others growing. That tells us aging is reshaping this region in a very specific, structured way.”
The researchers applied machine-learning models to distinguish Alzheimer’s disease cells from control cells using gene expression alone. Their findings indicated that the most important genes centered on two themes, inflammation and circadian rhythm. “At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD,” they stated.
Microglia, the brain’s resident immune cells, showed the largest number of altered genes. When the researchers ordered cells along a young-to-old-to-Alzheimer’s path, microglia gradually shifted from a resting state toward the “disease-associated” state seen in other Alzheimer’s disease studies. “This finding suggests that the hypothalamus transitions to an inflammatory state early in Alzheimer’s disease, just like the brain regions involved in memory,” said Webb. The authors further noted in their report, “Consistent with other brain regions, microglia, which are widely recognized mediators of brain aging and neurodegeneration, emerged as particularly prone to transcriptional reprogramming in the hypothalamus in early AD, although our unpaired, cross-sectional data cannot establish a causal or directional relationship.”
The hypothalamus is a diverse area of the brain, harboring many distinct cell types critical for its varied physiological roles. The scientists identified 254 neuron subtypes and found that inhibitory (GABAergic) neurons changed the most, mainly in neuropeptide and receptor signaling. One prominent group of neurons in the SCN showed disrupted signaling by vasopressin, a key output of the body’s clock.
“Sleep and circadian problems are some of the earliest signs of Alzheimer’s, and circadian behavioral changes known as sundowning, occur later in the disease,” Webb said. “But we’ve never had a good molecular explanation for why. Seeing vasopressin signaling disrupted in the brain’s master clock, in people at early stages of the disease, gives us a concrete place to start.”
Total cell numbers did not appear to change. Instead, the data point to cells getting larger through increased activity of mTOR, a growth pathway, along with remodeling of material between cells and inflammatory activation of glia. The authors present this as a hypothesis for future work.
They also noted several limits to their study, including the small autopsy cohort of 14 donors, which is typical for this kind of study. The MRI and sequencing data come from different people, so the two are compared side by side rather than combined statistically. And because the design is cross-sectional, the results show associations, not cause and effect.
“This is a starting point, not the final word,” Webb said. “Our next step is to follow these changes over time and test whether protecting the brain’s clock, and neuropeptide signaling in particular, can slow the disease or help manage symptoms. If circadian disruption is one of the first things to go wrong, it may also be one of the first places we can intervene.”
In their paper, the team commented, “HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression … We highlight notable vulnerabilities in GABAergic and/or inhibitory neurons, SCN and DMH circadian regulators, and inflammatory microglial cascades, underscoring their potential roles in instigating early hypothalamic dysfunction.”
The post Alzheimer’s Disease and Aging Linked to Changes in the Hypothalamus appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
